Global Lyme Disease Testing Market Growth (Status and Outlook) 2023-2029

Global Lyme Disease Testing Market Growth (Status and Outlook) 2023-2029

Lyme disease is caused by the bacterium Borrelia burgdorferi and rarely, Borrelia mayonii. It is transmitted to humans through the bite of infected blacklegged ticks. Typical symptoms include fever, headache, fatigue, and a characteristic skin rash called erythema migrans. Lyme disease is usually diagnosed by serology. RIPL uses a modified 2-tier testing approach. The initial screening test is a combined IgG and IgM ELISA that detects antibodies against 2 Borrelia burgdorferi antigens – VlsE1 and pepC10.

LPI (LP Information)' newest research report, the “Lyme Disease Testing Industry Forecast” looks at past sales and reviews total world Lyme Disease Testing sales in 2022, providing a comprehensive analysis by region and market sector of projected Lyme Disease Testing sales for 2023 through 2029. With Lyme Disease Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Lyme Disease Testing industry.

This Insight Report provides a comprehensive analysis of the global Lyme Disease Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Lyme Disease Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Lyme Disease Testing market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Lyme Disease Testing and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Lyme Disease Testing.

The global Lyme Disease Testing market size is projected to grow from US$ 196.2 million in 2022 to US$ 311.6 million in 2029; it is expected to grow at a CAGR of 6.8% from 2023 to 2029.

Global key players of Lyme Disease Testing include Quidel Corporation, Roche Holding AG and Fujirebio(H.U. Group Holdings), etc. Global top three manufacturers hold a share about 25%. North America is the largest market of Lyme Disease Testing, with a share over 60%, followed by Asia-Pacific and Europe.

This report presents a comprehensive overview, market shares, and growth opportunities of Lyme Disease Testing market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
ELISA
Western Blotting
PCR
Others

Segmentation by application
Hospital and Testing Agency
Personal

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Quidel Corporation
Roche Holding AG
Fujirebio(H.U. Group Holdings)
ZEUS Scientific
IGeneX
Thermo Fisher Scientific
Everlywell
Oxford Immunotec Global PLC(PerkinElmer)
BioMerieux
Bio-Rad Laboratories
T2 Biosystems

Please note: The report will take approximately 2 business days to prepare and deliver.